Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Brian A Walker, PhD, Frits van Rhee, MD PhD

Blood (2019) 134 (Supplement_1): 4383.

https://doi.org/10.1182/blood-2019-130493

Published: 2019

Journal Articles

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Tarun K. Garg, PhD, Cody Ashby, PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Shmuel Yaccoby, PhD

Blood (2019) 134 (Supplement_1): 4412.

https://doi.org/10.1182/blood-2019-127382

Published: 2019

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance

Michael A Bauer, PhD, Matthew Henry, M.S., Purvi Patel, Yan Wang, Joshua Epstein, DSc, Faith E. Davies, MD, Carolina D. Schinke, MD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Gareth Morgan, MD, Brian A Walker, PhD, Sarah K Johnson, PhD

Blood (2018) 132 (Supplement 1): 4465.

https://doi.org/10.1182/blood-2018-99-119131

Published: 2018

Journal Articles

Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma

Leo Rasche, Manoj Kumar, MD, Grant Gershner, James E McDonald, BS, MD, Samrat Roy Choudhury, PhD, Rudy L. Van Hemert, MD, Joshua Epstein, DSc, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Faith E. Davies, MD, Gareth Morgan, MD, Niels Weinhold, PhD

Blood (2018) 132 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2018-99-119759

Published: 2018

Journal Articles

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

Jeffery R. Sawyer, Erming Tian, PhD MBA, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Joshua Epstein, DSc, Janet L Lukacs, Gael M. Sammartino, Clyde Bailey, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Faith E. Davies, MD, Frits van Rhee, MD PhD, Gareth Morgan, MD

Blood (2018) 132 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2018-99-115090

Published: 2018

Journal Articles

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, PhD, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2018-99-115244

Published: 2018

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Brian A Walker, PhD, Cody Ashby, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2018-99-116455

Published: 2018

Journal Articles

Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Joshua Epstein, DSc, Brian A Walker, PhD, Frits van Rhee, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD

Blood (2018) 132 (Supplement 1): 3166.

https://doi.org/10.1182/blood-2018-99-117459

Published: 2018

Journal Articles

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

Blood (2018) 132 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2018-99-119249

Published: 2018

Journal Articles

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

Blood (2018) 132 (1): 59–66.

https://doi.org/10.1182/blood-2018-04-842880

Published: 2018

Includes: Supplemental data

Journal Articles

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

Whitney Tevebaugh, James Douglas, MS, Brian A Walker, PhD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E. Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J. Morgan, MD PhD, Sarah K Johnson, PhD

Blood (2017) 130 (Supplement 1): 4392.

https://doi.org/10.1182/blood.V130.Suppl_1.4392.4392

Published: 2017

Journal Articles

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Leo Rasche, MD, Tobias Meissner, PhD, Grant Gershner, Cody Cody Ashby, PhD, Ruslana G. Tytarenko, MS, Owen W. Stephens, Michael Bauer, PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Bart Barlogie, MD PhD, Brian A Walker, PhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4372.

https://doi.org/10.1182/blood.V130.Suppl_1.4372.4372

Published: 2017

Journal Articles

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Leo Rasche, MD, Carolina D. Schinke, MD, Daisy Alapat, MD, Grant Gershner, Sarah K Johnson, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, James E McDonald, BS, MD, Rohan Samant, MD, Edgardo Angtuaco, MD, Brian A Walker, PhD, Bart Barlogie, MD PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Niels Weinhold, PhD

Blood (2017) 130 (Supplement 1): 4510.

https://doi.org/10.1182/blood.V130.Suppl_1.4510.4510

Published: 2017

Journal Articles

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Joshua Epstein, DSc, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Maurizio Zangari, MD, Pingping Qu, Antje Hoering, Frits van Rhee, MD PhD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Christopher P. Wardell, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD, Shmuel Yaccoby, PhD

Blood (2017) 130 (Supplement 1): 1790.

https://doi.org/10.1182/blood.V130.Suppl_1.1790.1790

Published: 2017

Journal Articles

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Tarun K. Garg, PhD, Katie Stone, BS, Amy Greenway, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD, Joshua Epstein, DSc, Brian A Walker, PhD, Hing C Wong, PhD, Emily K Jeng, Niraj Shrestha, Faith E Davies, MD, Gareth J. Morgan, MD PhD, Frits van Rhee, MD PhD

Blood (2017) 130 (Supplement 1): 5452.

https://doi.org/10.1182/blood.V130.Suppl_1.5452.5452

Published: 2017

Journal Articles

Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma

Blood (2017) 130 (1): 30–34.

https://doi.org/10.1182/blood-2017-03-774422

Published: 2017

Includes: Supplemental data

Journal Articles

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma

Ya-Wei Qiang, Shiqiao Ye, Yu Chen, Amy F. Buros, Ricky Edmonson, Frits van Rhee, Bart Barlogie, Joshua Epstein, Gareth J. Morgan, Faith E. Davies

Blood (2016) 128 (25): 2919–2930.

https://doi.org/10.1182/blood-2016-03-706077

Published: 2016

Includes: Supplemental data

Journal Articles

The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Amy Buros, PhD, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 1138.

https://doi.org/10.1182/blood.V128.22.1138.1138

Published: 2016

NARROW

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

The mTOR Component, Rictor, Is Regulated By the Microenvironment to Control Dormancy and Proliferative States in Myeloma Cells

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Expression Signature of Myeloma Residual Cells Is Characterized By Genes Associated with Proliferation, Epigenetic Modification, and Stem Cell Maintenance

Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma

An Acquired High-Risk Chromosome Instability Phenotype in Multiple Myeloma: Jumping 1q Syndrome

Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

Analysis of the Metabolic State of Residual Multiple Myeloma Plasma Cells Reveals a Proliferative Subset with Glycolytic Gene Expression

Spatial Genomic Heterogeneity in Multiple Myeloma: Surrogate Markers and Its Significance for Understanding the Evolutionary Processes Leading to Relapse

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

Single-Cell Analysis of Mesenchymal Stem Cells Reveals Their Molecular and Functional Heterogeneity in Myeloma

The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells

Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma

The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only